store at low temperature
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Narciclasine (Lycoricidinol), a natural product, modulates the Rho/Rho-kinase/LIM kinase/cofilin signaling pathway, greatly increasing GTPase RhoA activity.
パッケージサイズ | 在庫状況 | 単価(税別) | |||
---|---|---|---|---|---|
サンプルについてお問い合わせ | |||||
1 mg | 在庫あり | ¥ 22,500 | |||
5 mg | 在庫あり | ¥ 99,000 | |||
10 mg | 在庫あり | ¥ 146,500 | |||
25 mg | 在庫あり | お問い合わせ | |||
50 mg | 在庫あり | お問い合わせ | |||
1 mL * 10 mM (in DMSO) | 在庫あり | ¥ 108,500 |
説明 | Narciclasine (Lycoricidinol), a natural product, modulates the Rho/Rho-kinase/LIM kinase/cofilin signaling pathway, greatly increasing GTPase RhoA activity. |
In vitro | Narciclasine activates Rho and stress fibers in glioblastoma multiforme cells (mean IC50: ~50 nM on the 6 human glioblastoma multiforme). The mean IC50 value of 47 nM for Narciclasine across a panel of 60 cancer cell lines [1]. The IC50 measured for radicle growth inhibition is 0.1 μM for Narciclasine [2]. |
In vivo | The i.v. regimen of Narciclasine at 1 mg/kg significantly increases the survival of GL19 glioblastoma multiforme-bearing mice. Narciclasine when given orally at the same dose five times a week for 5 consecutive weeks also significantly increases animal survival in this model. Oral treatment with Narciclasine at 1 mg/kg significantly increases the survival of Hs683 glioblastoma multiforme-bearing mice. Increasing the number of doses administered per week does not increase the survival of these Hs683 glioblastoma multiforme-bearing mice [1]. |
細胞研究 | The Narciclasine IC50 concentration, the Narciclasine concentration that decreased by 50% the global growth rate of a given cell population, is assessed with the MTT assay. The cells are incubated for 72 h in the presence and absence of the Narciclasine (with concentrations ranging between 1 and 10000 nM concentrate) for the determination of Narciclasine IC50 values [1]. |
動物実験 | The Hs683 cell line and GL19 primoculture grafted into the brains of nude immunodeficient mice both produced invasive brain tumors. Xenograft-bearing mice receive vehicle alone, oral temozolomide at 40 mg/kg (5 administrations per week for 5 consecutive weeks), or Narciclasine at 1 mg/kg either oral (once per week for 5 weeks) or i.v. (twice per week for 5 weeks). Drug administration is initiated respectively on days 5 and 7 post-tumor graftings for the Hs683 and GL19 models. The temozolomide dose and treatment schedule are selected based on previously optimized regimens. Narciclasine dose and treatment schedule are selected based on Narciclasine toxicity study in rats after oral administration and pharmacokinetic study that we have recently published. In toxicity study, Narciclasine (25, 10, or 1 mg/kg) is administered five times a week for 3 weeks and the no adverse effect level dose is defined to be 1 mg/kg/d p.o., with minimal acanthosis reactive changes and minor variations in some biochemistry parameters observed at this dose level considered to be nonadverse [1]. |
別名 | Lycoricidinol |
分子量 | 307.26 |
分子式 | C14H13NO7 |
CAS No. | 29477-83-6 |
store at low temperature
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 25 mg/mL (81.37 mM)
You can also refer to dose conversion for different animals. 詳細
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
Narciclasine 29477-83-6 Cell Cycle/Checkpoint Cytoskeletal Signaling Stem Cells ROCK Rho-associated kinase inhibit Inhibitor ROK Lycoricidinol Rho-associated protein kinase Rho-kinase inhibitor